Table 5.
Clinical events
| Clinical event, n (%) | All patients (N = 49) | Adult patients (n = 40) | Pediatric patients (n = 9) |
|---|---|---|---|
| Kidney transplantation | |||
| Before or at ravulizumab initiation | 15 (31) | 15 (38) | 0 |
| After ravulizumab initiationa | 0 | 0 | 0 |
| Last follow-up | 0 | 0 | 0 |
| Dialysis | |||
| Before or at ravulizumab initiation | 28 (57) | 26 (65) | 2 (22) |
| Ongoing at ravulizumab initiation | 4 (8) | 4 (10) | 0 |
| After ravulizumab initiation | 0 | 0 | 0 |
| Ongoing at last follow-up | 4 (8) | 4 (10) | 0 |
a
One patient reverted to eculizumab (per local guidelines) for a planned kidney transplantation with the intention to return to ravulizumab post transplantation.